

THE PROGNOSTIC SIGNIFICANCE OF SOME BIOLOGICAL MARKERS IN MESOTHELIOMA PATIENTS

A Thesis

**Submitted in Partial Fulfillment of
the Master Degree of Science
in Biochemistry**

By

**Gehan Sayed Abd El-kader H. Farahat
(B.Sc. Biochemistry, 2001)**

Under Supervision of

**Prof. Dr. Amr Youssef Esmat
Professor of Biochemistry
Department of Biochemistry
Faculty of Science
Ain Shams University**

**Prof. Dr. Ibrahim M. Abdel-Salam
Professor of Biochemistry
Department of Cancer Biology
National Cancer Institute
Cairo University**

**Dr. Omneya M. Sayed Hosny
Assistant Professor of Biochemistry
Department of Biochemistry
Faculty of Biochemistry
Ain Shams University**

**Department of Biochemistry
Faculty of Science
Ain Shams University**

2009



Ain Shams University
Faculty of Science
Biochemistry Department

Biography

Name : Gehan Sayed Abd El-kader Farahat

Date of Graduation: May, 2001

Faculty : Science

Department : Biochemistry

University : Ain Shams

ACKNOWLEDGMENTS

First of all, I should thank Allah, the most Gracious, the most Beneficial and the most Merciful for His help and guidance in my whole life and throughout this study.

*I would like to express my sincere appreciation and deepest gratitude to Prof. **Dr. Amr Youssef Esmat**, Professor of Biochemistry, Department of Biochemistry, Faculty of Science, Ain Shams University for his perpetual support and guidance, fruitful discussion and profound reviewing of the results and discussion of the manuscript.*

*I am also grateful to Prof. **Dr. Ibrahim M Abdel-Salam**, Professor of Biochemistry, Department of Cancer Biology, National Cancer Institute, Cairo University, for suggesting the points of this study, providing the laboratory facilities necessary for the experimental work and his continuous help and encouragement.*

*Deep thanks are also due to **Dr. Omneya M Sayed Hosny**, Assistant Professor of Biochemistry, Department of Biochemistry, Faculty of Science, Ain Shams University, for her advice, kind help, sincere encouragement and criticism throughout the course of the study.*

*I would like to express my thanks to **Dr. Rabab M. Gaffer**, Prof. of Medical Oncology, and **Dr. Abdel-Rahman M. Abdel-Rahman**, Assistant Professor of Surgical Oncology, National Cancer Institute (NCI), Cairo University, for the clinical diagnosis of the patients and providing me with the samples.*

Special thanks are also due to my family for their encouragement.

CONTENTS

Abstract-----	i
List of Abbreviations -----	iii
List of Table -----	vi
List of Figures -----	ix
Introduction -----	xiii
Aim of the Work -----	xviii

CHAPTER (I): REVIEW OF THE LITERATURE

▪ CANCER-----	1
• Anatomy and embryology of the pleura -----	1
• Blood supply -----	6
• Lymphatic drainage -----	7
• Nerve supply -----	7
• The Difference between the pleural fluid and pleural effusion -----	7
-Transudates pleural effusion -----	8
- Exudates pleural effusion -----	9
- Empyema-----	9
- Hemothorax or hemorrhagic-----	9
- Chylous or chyliform pleural effusion -----	9
• Definition of pleural mesothelioma -----	9
• Epidemiology -----	10
- Incidence-----	10

• Other localizations of malignant mesothelioma -----	11
- Peritoneal malignant mesothelioma -----	11
- Malignant mesothelioma of the tunica vaginalis testis -----	11
- Malignant mesothelioma of the pericardium -----	12
• Benign forms of mesothelioma -----	12
• Malignant mesothelioma (MM) -----	12
- Epithelial -----	12
- Sarcomatoid (fibrous) -----	12
- Biphasic (mixed) -----	13
• Classification of primary tumor of pleura -----	15
• Staging -----	16
• Causes of mesothelioma -----	17
- Asbestos exposure -----	17
Pathway of pathogenicity of asbestos fibre -----	19
Asbestos in Egypt -----	20
- Erionite -----	21
- Organic chemicals -----	21
- SV ₄₀ (Simian Virus- 40) -----	21
- Oncogenes -----	24
- Tumor suppressor genes -----	24
• TREATMENT -----	26
- Surgery -----	27
- Radiation therapy -----	27
- Chemotherapy -----	27
Antimetabolites -----	28
-Gemcitabine (Gemzar) -----	28

-Platinum analogs -----	30
Combination therapy-----	32
▪ TELOMERASE -----	33
• Telomerase and cell replication-----	34
• Senescence and immortalization -----	35
• Telomerase and cancer-----	36
• Regulation of telomerase activity -----	37
▪ ANGIOGENESIS -----	40
• Vascular endothelial growth factor (VEGF) -----	40
▪ INSULIN –LIKE GROWTH FACTOR-I (IGF-I) -----	43
• Hybrid receptors-----	47
• IGF-I and cancer-----	48
▪ LIPID PEROXIDATION -----	50
• Malondialdehyde (MDA) as a marker of lipid peroxidation	
• The effect of MDA on cell cycle kinetics, the expression	
andbiochemical activity of several cell cycle regulatory	
proteins-----	50

CHAPTER (II): SUBJECTS AND METHODS

▪ SUBJECTS-----	53
• Cases -----	53
• Design Study -----	58
• Samples -----	59
▪ METHODS-----	62
• Detection of Simian Virus 40 (SV40) in srum and uine of	
msothelioma ptients -----	62
• Detection of Telomerase Activity in Pleural Tissue and	
Effusion of Mesothelioma Patients-----	68

• Determination of the Total Protein Concentration in Tissue and Pleural Effusion Samples -----	75
• Determination of Serum Vascular Endothelial Growth Factor (sVEGF)-----	76
• Determination of Serum Insulin-Like Growth Factor-I (sIGF-I) -----	82
• Determination of Lipid Peroxides (Malondialdehyde) -----	86
STATISTICAL ANALYSIS -----	88
CHAPTER (III):RESULTS -----	93
CHAPTER (IV):DISCUSSION	
Discussion -----	132
SUMMARY -----	154
CONCLUSIONS -----	158
REFERENCES-----	160
ARABIC SUMMARY -----	
ARABIC ABSTRACT -----	

LIST OF ABBREVIATIONS

ADCC-----	Antibody dependent cellular cytotoxic
ALS -----	Acid-labile subunit
APC -----	Antigen-presenting cells
BCG-----	Bacillus calmette-guerin
CDDP -----	Cisdiamminedichloroplatinum
CDK-----	Cyclin-depenent kinase
CEA -----	Carcinoembryonic antigen
dFdCDP -----	Difluorodeoxycytidine diphosphate
dFdCTP-----	Difluorodeoxycytidine triphosphate
DLN-----	Draining lymph node
EGF -----	Epidermal growth factor
EGFR -----	Epidermal growth factor receptor
EMA -----	Epithelial membrane antigen
EPP -----	Extrapleural pneumonectomy
FACS -----	Fluorescence activated cell sorting
FGF -----	Fibroblast growth factor
flt-1-----	fms-like tyrosine kinase
GM-CSF-----	Granulocyte-macrophage colony-stimulating factor
IFN- α -----	Interferon-alpha
IFN- γ -----	Interferon gamma
IGFBPs -----	Insulin growth factor -binding proteins

IGF-I -----	Insulin like- growth factor-I
IGF-IR -----	Insulin like-growth factor-I receptor
IGF-IIR -----	Insulin like- growth factor-II receptor
IL-2-----	Interleukin-2
IR -----	Insulin receptor
IRS -----	Insulin receptor substrate
Kb -----	kilobase
KDR-----	Kinase domain receptor
LAK-----	Lymphokine-activated killer
LDH -----	Lactate dehydrogenase
M6P -----	Mannose-6-phosphate
MAPK -----	Mitogen-activated protein kinase
MCCs-----	Mesothelial cell cultures
MDA -----	Malondialdehyde
MDM2-----	Mouse double –minute 2
MHC -----	Major histocompatibility complex
MM-----	Malignant mesothelioma
MPM-----	Malignant pleural mesothelioma
MTX -----	Antifolate methotrexate
NF2-----	Neurofibromatosis type 2 gene
NK-----	Natural killer
NMR -----	Nuclear magnetic resonance
P/D -----	Pleurectomy and decortication
PAS -----	Periodic acid-Schiff stain
PCNA -----	Proliferating cellular nuclear antigen
PCR -----	Polymerase chain reaction

PDGF -----	Platelet-derived growth factor
PI3-kinase -----	Phosphatidyl inositol 3-kinase
PLGF-----	Placenta growth factor
pRb-----	Phosphoprotein of retinoblastoma
RNA-----	Ribonucleic acid
RTK -----	Receptor tyrosine-kinase
RT-PCR -----	Reverse transcriptase-PCR.
SMRP -----	Serum mesothelin-related protein
SV 40 -----	Simian virus-40
TERT -----	Telomerase reverse transcriptase
TGF- α / β -----	Transforming growth factor-alfa/ beta
TH1 -----	T-cell-helper 1
TNF- α -----	Tumor necrosis factor alpha
TRAP -----	Telomeric repeat amplification protocol
VEGF -----	Vascular endothelial growth factor
WT1-----	Wilm's tumor gene
β -FGF-----	Beta- Fibroblast growth factor

LIST OF FIGURES

Fig. (I-1): Normal lung anatomy-----	2
Fig. (I-2): Anatomy of the lung -----	3
Fig. (I-3): Anatomy of the pleura -----	4
Fig. (I-4): The parietal pleura is the primary site of entry and exit of fluid and protein-----	6
Fig. (I-5): Types of mesothelioma tissue -----	14
Fig. (I-6): Exposure to asbestos fibers can cause cancer -----	18
Fig. (I-7): Model of the p53 cell cycle regulatory pathway -----	26
Fig. (I-8): Structural formula of gemcitabine -----	29
Fig. (I-9): Structural formula of cisplatin-----	31
Fig. (I-10): The mechanism of action of cisplatin and its targets-	32
Fig. (I-11): Telomerase structure -----	34
Fig. (I-12): Regulation of telomerase activity-----	38
Fig. (I-13): IGF-I and signaling transduction cascades -----	44
Fig. (I-14): The IGF system -----	45
Fig. (I-15): Hybrid receptors of IGF -----	48

Fig. (II-1): A Pie chart shows the age distribution of the selected mesothelioma patients -----	53
Fig. (II-2)- Data of selected mesothelioma patients-----	57
Fig. (II-3): Schematic representation of ACCUCYTE®'s competitive enzyme immunoassay-----	77
Fig. (II-4): The standard curve of sVEGF-----	81
Fig. (II-5): The standard curve of sIGF-I-----	85
Fig. (III-1): Detection of DNA of SV40 on agarose gel electrophoresis then visualized under UV light -----	103
Fig. (III-2): Change percent of serum VEGF level ($\pm$ S.E) in mesothelioma patients before and during treatment compared to normal controls (0%) -----	108
Fig. (III-3): The cut-off value of serum VEGF level (645 pg/ml)-----	110
Fig. (III-4): Change percent of serum VEGF Level ($\pm$ S.E) in mesothelioma patients before and during treatment and with or without lymph nodes involvement compared to normal controls (0%) -----	112
Fig. (III-5): Change percent of serum VEGF Level ($\pm$ S.E) in the different histological types of mesothelioma (epithelial, biphasic and sarcomatous) compared to normal controls (0%)-----	114

Fig. (III-6): Change percent of serum IGF-I Level ($\pm$ S.E) in mesothelioma patients before and during treatment compared to normal controls (0%) ----- 116

Fig. (III-7): Change percent of serum IGF-I Level ($\pm$ S.E) in mesothelioma patients before and during treatment and with or without lymph nodes involvement compared to normal controls (0%) ----- 116

Fig. (III-7): Change percent of serum IGF-I level ($\pm$ S.E) in the different histological types of mesothelioma (epithelial, biphasic and sarcomatous) compared to normal controls (0%)----- 118

Fig. (III-8): Change percent of serum MDA level ($\pm$ S.E) in mesothelioma patients before and during treatment compared to normal controls (0%) ----- 120

Fig. (III-9): Change percent of serum MDA Level ($\pm$ S.E) in mesothelioma patients before and during treatment and with or without lymph nodes involvement compared to normal controls (0%) ----- 122

Fig. (III-10): Change percent of serum MDA level ($\pm$ S.E) compared to normal controls (0%) in the different histological types of mesothelioma (epithelial, biphasic and sarcomatous)-- 124

Fig. (III-11): Change percent of urinary MDA level ($\pm$ S.E) in mesothelioma patients before and during treatments compared to normal controls (0%) ----- 126

Fig. (III-12): Change percent of urinary MDA level ($\pm$ S.E) in mesothelioma patients with or without lymph nodes involvement compared to normal controls (0%)----- 128

Fig. (III-13): Change percent of urinary MDA level ($\pm$ S.E) compared to normal controls (0%) in the different histological types of mesothelioma (epithelial, biphasic and sarcomatous)-- 130